An interventional study of double polymorphism in High Blood Pressure, sponsored by Centre Hospitalier Universitaire de la Guadeloupe. Recruiting at 2 sites in Guadeloupe. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-01-09.
Sponsored by Centre Hospitalier Universitaire de la Guadeloupe · Not applicable, Interventional, and Diagnostic
Cardiovascular disease (CVD) mortality is the leading cause of death in high-income countries (particularly the United States), accounting for 23.1% of all deaths It has been established over several decades that hypertension disproportionately affects African Americans, compared with Americans of European descent:Hypertension occurs more often, at an earlier age , with greater severity , and is associated with an approximately 3-fold higher probability of death .There is also poorer control of hypertension despit e similar treatment In African Americans, CVD morbidity and mortality are compounded by the higher prevalence of T2DM, obesity, CKD, stroke, and heart failure . Despite advances in the identification of risk factors and the availability of effective treatment in hypertension, CVD disparities, persist among African Americans and are expected to increase in the future, particularly in younger age groups. Although various environmental and social factors certainly contribute to these disparities, a genetic basis, involving numerous "candidate" genes, is most often asserted in the literature . One of these is the Corin gene (Pan et al, 2002) which codes for the Corin protein.The latter plays a pivotal role in cardiometabolic pathophysiology through its role in the activation of natriuretic peptides .Natriuretic peptides (ANP and BNP) have a major role in the regulation of blood pressure through their vasodilatory and diuretic action. They have a lusotropic action, inhibit the renin angiotensin system, and are involved in energy metabolism (increased lipolysis and insulin secretion). They also have an anti-fibrotic, anti-proliferative, anti-inflammatory and anti-thrombotic action.The Corin gene of 244109pb has many variants that produce an inefficient protein with the corollary of the appearance of metabolic and cardiovascular pathologies in the first rank of which the HTA, the cardiac insufficiency and the renal insufficiency .Recently, a double polymorphism of the Corin gene consisting of 2 SNPs (single nucleotide polymorphisms) on the same allele of the Corin gene (I555/P568) has been reported. This allele is present in the heterozygous state in 12% of African Americans but is extremely rare in Americans of European descent (\<0.5%).This double polymorphism (I555/P568) has been shown to be responsible for an approximately 70% reduction in the ability of the mutated Corin protein to convert proANP or proBNP to the active form. In addition, the I555(P568) allele of Corin protein is associated with an increased risk of hypertension and concentric cardiac hypertrophy The corin allele (I555/P568) is reported to be associated with poorer response to validated heart failure therapy and a higher risk of death or hospitalization for heart failure .
In Guadeloupe, where the population is predominantly of African descent.Cardiovascular disease is the leading cause of mortality.The prevalence of hypertension is 39% and more than 50% after 50 years of age . It has increased by 10% in 10 years in Guadeloupe. In France, where the prevalence of hypertension is 31%, it has increased by only 5% over the same period.
Heart failure is the main cause of admission to the cardiological emergency room of the University Hospital (49%) with a mortality of 37% at 6 months. Hypertension is the first risk factor associated with heart failure (80%).To date, there are no studies on corin gene polymorphisms in Guadeloupe. Following the example of work already done in the African American population, we propose to study the role of the double polymorphism (I555/P568) in the determinism of hypertension in the population of African descent in Guadeloupe.
6,114 studies on the registry are indexed under Hypertension; 912 are open to participants now.
This study's planned enrollment of 370 is above the median of 100 across 4,575 interventional studies indexed under Hypertension.
Browse Hypertension studies →Centre Hospitalier Universitaire de la Guadeloupe is the lead sponsor of 50 studies on the registry; 25 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Case inclusion criteria
Control inclusion criteria:
Exclusion Criteria:
Patients, considering themselves to be of Afro-Caribbean origin with hypertension, treated for hypertension or diagnosed as carrying hypertension according to HAS recommendations (Prise en charge de l'Hypertension artérielle de l'adulte, sept 2016): "elevation of blood pressure (BP), including systolic blood pressure (SBP) ≥140 mmHg and/or diastolic blood pressure (DBP) ≥ 90 mmHg" measured in the doctor's office and confirmed over several consultations on the day of inclusion. The diagnosis of hypertension can also be made by self-measurement over 3 days (mean PAS \>135 mmHg and/or PAS\> 85 mmHg) or by ABPM (Ambulatory Blood Pressure Monitoring: Holter Tensionnel) with PAS \>135 mmHg and/or PAD \>85 mmHg for the daytime period (awake); PAS\>120 mmHg and/or PAD\> 70 mmHg for the nighttime period (asleep). In the case of hypertension, mean PAS \> 130 mmHg and PAD \> 80 mmHg. ESC/ESH 2018 recommendations
Diagnostic Test: double polymorphism
Patients who consider themselves to be of Afro-Caribbean origin, of the same sex and ± 5 years of age as the cases, with no diagnosis of hypertension. Controls will be recruited by the same physicians who included a person with hypertension, but consulting for any other symptoms.
Diagnostic Test: double polymorphism
diagnostic test
Also known as: cases
double polymorphism
1. Genotyping by capillary electrophoresis (Sanger sequencing): 2. Genotyping using the allelic discrimination method
Time frame: At day 15
heart failure
Frequency of heart failure in cases and controls
Time frame: At inclusion
Renal failure
Frequency of renal failure in cases and
Time frame: At Day 15
natriuretic peptid (NT PRO BNP)
natriuretic peptid assay in cases and controls
Time frame: At Day 15
créatinine clearance
creatinine clearance in MDRD in cases and controls
Time frame: At Day 15
Fasting blood glucose
Hb1AC measurement
Time frame: At Day 15
Cholesterolemia
measurement
Time frame: At Day 15
triglyceridemia
measurement
Time frame: At Day 15
Body Mass Index
Body mass Index calculation measurement in cases and controls
Time frame: At inclusion
waist
waist circumference measurement in cases and controls
Time frame: At inclusion
Left ventricular ejection fraction (LVEF)_systolic function in Simpson
pourcentage
Time frame: At 3 months for case, 12 months control
ECG measurements Cornell
mV
Time frame: At inclusion, or month 3 for case and month 12 for control
diastolic function E/ea ratio
ratio
Time frame: At inclusion, or month 3 for case and month 12 for control
parietal thickness
mm
Time frame: At inclusion, or month 3 for case and month 12 for control
left atrial size and volume
ml
Time frame: At inclusion, or month 3 for case and month 12 for control
ECG measurement Lewis
mV
Time frame: At inclusion, or month 3 for case and month 12 for control
ECG measurement Sokolow-Lyon
mV
Time frame: At inclusion, or month 3 for case and month 12 for control
ECG measurment Siegel
mV
Time frame: At inclusion, or month 3 for case and month 12 for control
ECG measurment Roberts
mV
Time frame: At inclusion, or month 3 for case and month 12 for control
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Centre Hospitalier Universitaire de la Guadeloupe